|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030956,
umls-concept:C0033684,
umls-concept:C0039195,
umls-concept:C0536940,
umls-concept:C0871261,
umls-concept:C1413787,
umls-concept:C1566673,
umls-concept:C1704632,
umls-concept:C1704858,
umls-concept:C1706817,
umls-concept:C2825965,
umls-concept:C2911692
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2004-9-15
|
|
pubmed:abstractText |
NY-ESO-1 is a germ cell antigen aberrantly expressed by different tumor types that elicits strong humoral and cellular immune responses, representing one of the most promising candidates for vaccination of cancer patients. A detailed analysis of CD8(+) T cells generated in vaccine trials using NY-ESO-1-derived peptides (157-165 and 157-167) revealed that the dominant immune response was directed against a cryptic epitope (159-167) diverting the immune response from tumor recognition. Only CTL reactivity to the NY-ESO-1(157-165) peptide appeared to be capable of lysing NY-ESO-1/HLA-A0201-expressing tumor cells. To study the process of NY-ESO-1 peptide presentation by tumor cells in more detail we generated a high-affinity (K(D)=60 nM) antibody fragment that specifically recognizes the NY-ESO-1(157-165) peptide/HLA-A0201 complex. Peptide variants such as the NY-ESO-1(157-167) peptide or the cryptic NY-ESO-1(159-167) peptide were not recognized. The antibody fragment blocked in a dose-dependent fashion the recognition of NY-ESO-1/HLA-A2-positive tumor cells by NY-ESO-1(157-165) peptide-specific CD8(+) T cells. This antibody fragment is a novel reagent that binds with TCR-like specificity to the NY-ESO-1(157-165)/HLA-A2 complex thus distinguishing between CTL responses against immunological meaningful or cryptic NY-ESO-1-derived peptides. It may therefore become a useful monitoring tool for the development of NY-ESO-1-based cancer vaccines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0014-2980
|
|
pubmed:author |
pubmed-author:CohenCyril JCJ,
pubmed-author:EpelMalkaM,
pubmed-author:GnjaticSachaS,
pubmed-author:HeldGerhardG,
pubmed-author:HoogenboomHennie RHR,
pubmed-author:LeeSang YullSY,
pubmed-author:MatsuoMitsutoshiM,
pubmed-author:OldLloyd JLJ,
pubmed-author:PfreundschuhMichaelM,
pubmed-author:ReiterYoramY,
pubmed-author:RennerChristophC,
pubmed-author:RitterGerdG,
pubmed-author:TaiTsin YeeTY
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2919-29
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15368308-Amino Acid Sequence,
pubmed-meshheading:15368308-Antibody Specificity,
pubmed-meshheading:15368308-Antigen Presentation,
pubmed-meshheading:15368308-Antigens, Neoplasm,
pubmed-meshheading:15368308-Cancer Vaccines,
pubmed-meshheading:15368308-Cell Line, Tumor,
pubmed-meshheading:15368308-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:15368308-Flow Cytometry,
pubmed-meshheading:15368308-Humans,
pubmed-meshheading:15368308-Immunodominant Epitopes,
pubmed-meshheading:15368308-Immunoglobulin Fab Fragments,
pubmed-meshheading:15368308-Major Histocompatibility Complex,
pubmed-meshheading:15368308-Membrane Proteins,
pubmed-meshheading:15368308-Peptides,
pubmed-meshheading:15368308-Protein Conformation,
pubmed-meshheading:15368308-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:15368308-Transfection
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
|
|
pubmed:affiliation |
Clinic for Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
